RxDoctor Payments Data

Joseph Dalovisio

Infectious Disease · New Orleans, LANPI 1548228968

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Novartis. That places this record below the midpoint for infectious disease clinicians in LA, where the typical reported total is $611.

$29in general payments, 2019–2025

Across 1 payment — averaging $29.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$29
$633,575in research payments, 2019–2025

Across 43 payments — averaging $14,734 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$634K

What the payments were for

  • Food & beverage$29100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis1$29

How this compares

$29 in reported general payments places this provider in the 10th percentile of 105 infectious disease providers in Louisiana.

See all infectious disease providers in Louisiana

Other infectious disease in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →